コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 adolinium species found in rats treated with gadoteridol.
2 rior to administration of the second dose of gadoteridol.
3 d with the macrocyclic agents gadobutrol and gadoteridol.
4 st agent leakage correction for imaging with gadoteridol.
5 ased sharply for both agents-but more so for gadoteridol.
6 cartilage with the nonionic contrast agent, gadoteridol.
7 chnique by using a mean dose of 0.18 mmol/kg gadoteridol.
8 differences were not seen in the presence of gadoteridol.
9 ng a single breath hold, enhanced with 30 mL gadoteridol.
10 ere obtained after right atrial injection of gadoteridol (0.025 mmol/kg) with an MRI inversion recove
11 f pregnancy, the macaques were injected with gadoteridol (0.1 mmol per kilogram of maternal weight).
12 us injection of gadopentetate dimeglumine or gadoteridol (0.1 mmol/kg), nine images were acquired at
13 n addition, we found that the small molecule gadoteridol accumulates around and within ablated tissue
15 age the distribution inside mouse kidneys of gadoteridol, an exogenous magnetic resonance contrast ag
16 roxyethylcellulose gel (semen simulant) with gadoteridol and dosed via artificial phallus after simul
17 were derived from perfusion MR imaging with gadoteridol and ferumoxytol in 19 patients with apparent
18 lic gadolinium-based contrast agents (GBCAs) gadoteridol and gadoterate meglumine in a pediatric coho
19 ased contrast agents (GBCAs) gadodiamide and gadoteridol and to quantify the amount of intact gadolin
22 o be a good prognostic biomarker, and unlike gadoteridol, does not require contrast agent leakage cor
23 luoroscopically triggered 3D MR angiography (gadoteridol dose range, 0.1-0.3 mmol per kilogram of bod
26 of 28 078 patients who underwent intravenous gadoteridol-enhanced MR imaging from July 2007 to Decemb
27 dimensional MR angiograms were obtained with gadoteridol enhancement, breath holding, and a three-dim
31 sues after in utero exposure to two doses of gadoteridol, indicating that a very small amount of gado
32 ue (95% confidence interval [CI]: 0, 0.2) in gadoteridol-injected rats, 1.6 mug gadolinium per gram o
34 ns and vasculature from the localization of [Gadoteridol+K](+) and [Gadoteridol+Na](+) adducts, respe
36 (MR) imaging after intravenous injection of gadoteridol (nonionic contrast agent; n = 6) or gadopent
37 contrast, administration of gadopentetate or gadoteridol produced no significant change in serum calc
38 rocyclic contrast agents (gadoteric acid and gadoteridol) produced a maximum stimulation of fibroblas
40 adolinium concentrations for gadodiamide and gadoteridol, respectively, were 0.317 mug/g +/- 0.060 (s
42 grown in mice were subjected to CA-MSI using Gadoteridol revealing tumor margins and vasculature from
43 ncement ratios were significantly higher for gadoteridol than for gadopentetate dimeglumine in the ph
47 ive-minute MR renography with a 3-mL dose of gadoteridol was performed instead of a routine test-dose
49 en leakage correction was applied, rCBV with gadoteridol was significantly associated with survival (
50 ved gadolinium (Gd)-based MR contrast agent, gadoteridol, was encapsulated within nanometer-sized pho
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。